Eli Lilly and Company (LLY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LLY Revenue Growth
Revenue Breakdown (FY 2025)
LLY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
LLY Revenue Analysis (2014–2025)
As of May 6, 2026, Eli Lilly and Company (LLY) generated trailing twelve-month (TTM) revenue of $72.25 billion, reflecting explosive growth of +55.5% year-over-year. The most recent quarter (Q1 2026) recorded $19.80 billion in revenue, up 2.6% sequentially.
Looking at the longer-term picture, LLY's 5-year compound annual growth rate (CAGR) stands at +21.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $65.18 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows LLY's business is primarily driven by Product (94%), and Collaboration and Other Revenue (6%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVO (+2.3% YoY), PFE (+1.4% YoY), and MRK (+1.2% YoY), LLY has outperformed the peer group in terms of revenue growth. Compare LLY vs NVO →
LLY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LLYCurrent | $72.2B | +55.5% | +21.6% | 45.6% | |
 NVO | $297.2B | +2.3% | +18.5% | 41.4% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 AZN | $58.7B | +9.9% | +17.2% | 23.4% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% |
LLY Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $65.18B | +44.7% | $54.62B | 83.8% | $29.70B | 45.6% |
| 2024 | $45.04B | +32.0% | $36.62B | 81.3% | $17.50B | 38.9% |
| 2023 | $34.12B | +19.6% | $27.04B | 79.2% | $10.79B | 31.6% |
| 2022 | $28.54B | +0.8% | $21.91B | 76.8% | $8.65B | 30.3% |
| 2021 | $28.32B | +15.4% | $21.01B | 74.2% | $7.93B | 28.0% |
| 2020 | $24.54B | +9.9% | $19.06B | 77.7% | $7.21B | 29.4% |
| 2019 | $22.32B | +3.8% | $17.60B | 78.8% | $6.00B | 26.9% |
| 2018 | $21.49B | +7.6% | $16.81B | 78.2% | $6.03B | 28.0% |
| 2017 | $19.97B | -5.9% | $15.53B | 77.7% | $4.25B | 21.3% |
| 2016 | $21.22B | +6.3% | $15.51B | 73.1% | $3.87B | 18.2% |
Full LLY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy LLY Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See LLY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LLY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LLY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLLY — Frequently Asked Questions
Quick answers to the most common questions about buying LLY stock.
Is LLY's revenue growth accelerating or slowing?
LLY revenue is accelerating at +55.5% year-over-year, exceeding the 5-year CAGR of +21.6%. TTM revenue reached $72.2B. Growth momentum has increased versus prior periods.
What is LLY's long-term revenue growth rate?
Eli Lilly and Company's 5-year revenue CAGR of +21.6% reflects the sustained expansion pattern. Current YoY growth of +55.5% is above this long-term average.
How is LLY's revenue distributed by segment?
LLY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.